Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biohaven Pharmaceutical Holding Co Ltd.

14.46
+0.07000.49%
Post-market: 14.460.00000.00%19:08 EDT
Volume:2.79M
Turnover:40.10M
Market Cap:1.48B
PE:-1.57
High:14.63
Open:14.48
Low:13.87
Close:14.39
Loading ...

Biohaven Says FDA Grants Priority Review to Neurodegenerative Disorder Drug; Shares Rise

MT Newswires Live
·
11 Feb

BRIEF-Biohaven Announces FDA Acceptance And Priority Review Of Troriluzole New Drug Application

Reuters
·
11 Feb

Biohaven Gets FDA Priority Review of Troriluzole for Spinocerebellar Ataxia

Dow Jones
·
11 Feb

Biohaven Ltd - FDA Decision on Troriluzole Nda Expected by 3Q2025

THOMSON REUTERS
·
11 Feb

Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia

THOMSON REUTERS
·
11 Feb

Biohaven Ltd - Prepared to Commercialize Troriluzole for SCA in 2025

THOMSON REUTERS
·
11 Feb

Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia

PR Newswire
·
11 Feb

Deutsche Bank Initiates Coverage on Biohaven With Buy Rating, $65 Price Target

MT Newswires Live
·
11 Feb

Biohaven Ltd : Deutsche Bank Initiates Coverage With Buy Rating; Price Target $65

THOMSON REUTERS
·
11 Feb

Pfizer to pay ~$60M to settle Medicare false claims

TIPRANKS
·
25 Jan

Bernstein Sticks to Their Buy Rating for Biohaven Ltd. (BHVN)

TIPRANKS
·
14 Jan

Biohaven announces 2025 anticipated milestones

TIPRANKS
·
14 Jan

Biohaven enters multi-target collaboration with Merus

TIPRANKS
·
14 Jan

Merus, Biohaven Partner to Develop Bispecific Therapies for Cancers

MT Newswires Live
·
13 Jan

BRIEF-Merus And Biohaven Announce Collaboration To Co-Develop Three Novel Bispecific ADC Programs

Reuters
·
13 Jan

Biohaven - Agreement Includes Two Merus Bispecific Programs Generated Using Biclonics Platform

THOMSON REUTERS
·
13 Jan

Biohaven Ltd - Co Is Responsible for Preclinical ADC Generation of Three Merus Bispecific Antibodies Under Mutually Agreed Research Plans

THOMSON REUTERS
·
13 Jan

Biohaven Ltd - Merus Will Receive an Upfront Payment and License Fee at ADC Candidate Nomination of First Program

THOMSON REUTERS
·
13 Jan

Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs

GlobeNewswire
·
13 Jan

Insider Buying: Biohaven Independent Director Bought US$1.0m Of Shares

Simply Wall St.
·
03 Jan